6.06
6.06 (0%)
As of Apr 17, 2025
89bio, Inc. [ETNB]
Source:
Company Overview
89bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases.
| Country | United States |
| Headquarters | san francisco, california |
| Phone Number | (415) 432-9270 |
| Industry | manufacturing |
| CEO | Rohan Palekar |
| Website | www.89bio.com. |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-384.7 |
| Net Income | $-367.1 |
| Net Cash | $-190.1 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -68.3% |
| Profit as % of Stockholder Equity | -91.6% |
Management Effectiveness
| Return on Equity | -91.6% |
| Return on Assets | -76.7% |
| Turnover Ratio | |
| EBITA | $-384.7 |
Balance Sheet and Cash Flow Measures
| Total Assets | $478.7 |
| Total Liabilities | $77.9 |
| Operating Cash Flow | $-367.8 |
| Investing Cash Flow | $-40.9 |
| Financing Cash Flow | $218.6 |
